IONS - Ionis hereditary angioedema therapy succeeds in late-stage trials
2024-05-31 07:46:06 ET
More on Ionis Pharmaceuticals
- Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
- Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
- Biogen also drops collaboration with Ionis on Angelman syndrome candidate
- Biogen and Ionis drop ALS candidate after trial setback
- Seeking Alpha’s Quant Rating on Ionis Pharmaceuticals